Literature DB >> 15246460

Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizotypal personality disorder.

Vivian Mitropoulou1, Marianne Goodman, Serge Sevy, Igor Elman, Antonia S New, Elisabeth G Iskander, Jeremy M Silverman, Alan Breier, Larry J Siever.   

Abstract

BACKGROUND: Stress has been associated with the onset of schizophrenia and exacerbation of psychotic symptoms. Patients with schizotypal personality disorder (SPD), the prototypic schizophrenia spectrum disorder, do not develop the frank psychosis of schizophrenia and appear clinically to be less reactive to stress than schizophrenic patients. Schizophrenic patients demonstrate increased dopaminergic (DA) and hypothalamic-pituitary-adrenal-axis (HPA) activation following 2-deoxyglucose (2-DG), an acute metabolic (glycopyruvic) stressor, compared to healthy volunteers (HV). We hypothesized that SPD patients would demonstrate comparable or lower DA and HPA responses after 2-DG to HV.
METHODS: Fifteen SPD patients and 13 HV were administered 2-DG (40 mg/kg, i.v.) in a double-blind, placebo-controlled, randomized protocol. The area under the curve (AUC) was determined for plasma HVA, ACTH and cortisol (utilizing baseline and post infusion indices).
RESULTS: 2-DG induced significant increases in ACTH, cortisol and HVA concentrations in both groups and cortisol elevations were significantly lower in patients with SPD than in HV.
CONCLUSIONS: Patients with SPD have a blunted cortisol and a normal dopaminergic response to 2-DG. These results are consistent with the hypothesis that SPD patients are better buffered against DA and HPA overactivation in response to stress.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246460     DOI: 10.1016/j.schres.2003.10.008

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  7 in total

Review 1.  How does studying schizotypal personality disorder inform us about the prodrome of schizophrenia?

Authors:  Katherine Seeber; Kristin S Cadenhead
Journal:  Curr Psychiatry Rep       Date:  2005-03       Impact factor: 5.285

2.  Deficient visual sensitivity in schizotypal personality disorder.

Authors:  Brendon W Kent; Zachary A Weinstein; Vincent Passarelli; Yue Chen; Larry J Siever
Journal:  Schizophr Res       Date:  2010-06-11       Impact factor: 4.939

Review 3.  Comorbid mood, psychosis, and marijuana abuse disorders: a theoretical review.

Authors:  Natascha Wilson; Jean Lud Cadet
Journal:  J Addict Dis       Date:  2009-10

4.  Cognitive function and symptoms in adolescents with schizotypal personality disorder.

Authors:  Hanan Trotman; Amanda McMillan; Elaine Walker
Journal:  Schizophr Bull       Date:  2006-04-12       Impact factor: 9.306

5.  Pituitary volume in schizophrenia spectrum disorders.

Authors:  F Romo-Nava; W S Hoogenboom; P E Pelavin; J L Alvarado; L H Bobrow; F P Macmaster; M Keshavan; R W McCarley; M E Shenton
Journal:  Schizophr Res       Date:  2013-03-19       Impact factor: 4.939

6.  Larger putamen size in antipsychotic-naïve individuals with schizotypal personality disorder.

Authors:  Eran Chemerinski; William Byne; Jeanine C Kolaitis; Cathryn F Glanton; Emily L Canfield; Randall E Newmark; M Mehmet Haznedar; Vladan Novakovic; King-Wai Chu; Larry J Siever; Erin A Hazlett
Journal:  Schizophr Res       Date:  2012-11-24       Impact factor: 4.939

7.  Are Expectations the Missing Link between Life History Strategies and Psychopathology?

Authors:  Phillip S Kavanagh; Bianca L Kahl
Journal:  Front Psychol       Date:  2018-02-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.